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Background	   and	   purpose:	   To	   find	   out	   factors	   associated	   with	   development	   of	  symptomatic	  intracranial	  haemorrhage	  (sICH)	  in	  patients	  with	  basilar	  artery	  occlusion.	  Patients	   were	   treated	   with	   intravenous	   alteplase	   and	   full-­‐dose	   anticoagulation	   with	  heparin.	  
Methods:	  The	  data	  is	  from	  a	  consecutive	  cohort	  of	  176	  BAO	  patients	  treated	  at	  Helsinki	  University	   Central	   Hospital	   during	   the	   period	   between	   1995-­‐2013.	   sICH	   was	   judged	  according	   to	   European	   Cooperative	   Acute	   Stroke	   Study	   II.	   The	   extent	   of	   baseline	  ischemia	   was	   evaluated	   with	   posterior	   circulation	   Acute	   Stroke	   Prognosis	   Early	   CT	  score	  (pc-­‐ASPECTS).	  Modified	  Rankin	  Scale	  (mRS)	  at	  three	  months	  was	  used	  to	  rate	  the	  outcome.	  Favourable	  outcome	  was	  rated	  as	  0	  to	  2	  and	  unfavourable	  as	  3	  to	  6.	  
Results:	   13.6%	   of	   patients	   developed	   sICH.	   Pc-­‐ASPECTS	   under	   8	   independently	  increased	  the	  risk	  of	  sICH	  (p	  =	  0.031).	  70.3%	  of	  patients	  had	  3-­‐month	  mRS	  3	  to	  6,	  among	  whom	   were	   all	   sICH	   cases.	   High	   mean	   systolic	   blood	   pressure	   two	   hours	   after	  thrombolysis	   was	   independently	   associated	   with	   development	   of	   sICH	   (p	   =	   0.034).	  Platelet	  count	  at	  baseline	  and	  24	  hours	  after	  tPA	  and	  heparin	  administration	  was	  lower	  in	  patients	  with	  sICH	  than	  without	  sICH.	  Activated	  partial	  thromboplastin	  time	  (APTT)	  values	  didn’t	  associate	  with	  developing	  sICH.	  
Interpretation:	  Low	  to	  normal	  platelet	  count,	  extensive	  baseline	  ischemic	  changes	  and	  high	  systolic	  blood	  pressure	  at	  2	  hours	  after	  treatment	  increased	  the	  risk	  of	  developing	  sICH.	  Avainsanat	  –	  Nyckelord	  –	  Keywords	  Anticoagulation,	  basilar	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  platelet,	  thrombolysis	  
	   ii	  




	   1	  
1	  	  	  	  	  Introduction	  
 Basilar	  artery	  occlusion	  (BAO)	  is	  a	  rare	  but	  severe	  form	  of	  brain	  infarction.	  About	  one	  per	  cent	  of	  all	  strokes	  is	  caused	  by	  BAO.	  Patients	  often	  have	  preceding	  non-­‐specific	  symptoms	  such	  as	  vertigo	   or	   headaches,	   which	   are	   followed	   by	   decreased	   consciousness,	   quadriparesis,	  pupillary	   and	   oculomotor	   abnormalities,	   dysarthria	   and	   dysphagia.	   (1)	   The	   onset	   of	  symptoms	   is	   slow	   in	   more	   than	   60%	   of	   cases	   and	   instantaneous	   in	   20%	   of	   cases.	   Most	  patients,	  more	  than	  99%,	  have	  two	  or	  more	  symptoms.	  (2)	  Differential	  diagnostic	  alternatives	  are	   intracranial	   bleeding	   including	   subarachnoid	   haemorrhage	   (SAH),	   non-­‐convulsive	  epileptic	   seizures,	   hypoxic-­‐ischemic	   encephalopathy	   and	   hypoglycaemia	   (3).	   The	   most	  frequent	  causes	  of	  BAO	  are	  atherosclerotic	  occlusions	  resulting	  from	  local	  thrombosis	  at	  the	  site	  of	  severe	  BA	  stenosis	  and	  embolic	  occlusions	  from	  cardiac	  and	  large	  artery	  sources	  (1).	  Diagnosis	   can	   be	   made	   on	   the	   basis	   of	   a	   cranial	   computed	   tomography	   (CT)	   with	   CT-­‐angiography,	   magnetic	   resonance	   angiography	   (MRA)	   or	   digital	   subtraction	   angiography	  (DSA)	  (3)	  .	  	  	  Treatment	  aims	  to	  recanalization	  of	  occluded	  basilar	  artery.	  If	  recanalization	  does	  not	  occur,	  85-­‐95%	   of	   patients	   will	   die.	   	   (3)	   	   Treatment	   alternatives	   are	   antithrombotic	   agents,	  intravenous	   thrombolysis	   (IVT),	   intra-­‐arterial	   thrombolysis	   (IAT),	   and	   mechanical	  endovascular	  treatment	  performed	  in	  an	  angio	  suite	  (1).	  Systematic	  analysis	  has	  shown	  that	  there	  is	  “no	  significant	  difference	  in	  functional	  independence	  with	  endovascular	  therapy	  after	  intravenous	  tissue	  plasminogen	  activator	  (tPA),	  as	  compared	  with	  intravenous	  tPA	  alone”	  in	  BAO	   (4).	  With	  mechanical	   endovascular	   treatment	   there	   can	   even	   be	   a	   90%	   recanalization	  rate	  but	   there	   is	  no	  evidence	  of	   superiority	  of	   endovascular	   treatment	  over	   IVT	  concerning	  clinical	  outcomes	  (1).	  	  Since	  no	  controlled	  randomized	  trials	  have	  compared	  these	  acute	  treatment	  options	  with	  each	  other,	   the	   choice	   of	   treatment	   is	   based	   on	   the	   local	   guidelines	   and	   accessibility.	   Further	  research	   is	   needed	   to	   secure	   improvements	   in	   the	   treatment	   of	   BAO	   (1).	   A	   third	   of	   BAO	  patients	   will	   become	   independent	   after	   thrombolysis.	   About	   half	   of	   patients	   with	  recanalization	  will	  become	  independent.	  (3)	  The	  long-­‐term	  quality	  of	  life	  of	  the	  survived	  BAO	  patients	  have	  rarely	  been	  systemically	  analysed	  (5).	  	  
	   2	  
	  In	   Finland,	   primary	   treatment	   for	   BAO	   is	   IVT	   with	   alteplase	   and	   concomitant	   intravenous	  heparin	  infusion.	  A	  requirement	  for	  IVT	  is	  that	  extensive	  ischemic	  changes	  in	  the	  brainstem	  or	  other	   vertebro-­‐basilar	   (VB)	   regions	   have	   not	   developed	   (6).	   Contraindications	   for	  thrombolytic	   therapy	  are	   a	  duration	  of	  BAO	  exceeding	  12	  hours	   in	   the	   instantaneous	  onset	  phenotype	  or	  48	  hours	  in	  the	  progressive	  (slow-­‐onset)	  phenotype,	  absent	  brain	  stem	  reflexes	  and/or	   a	   lack	   of	   spontaneous	   respiration,	   haemorrhage	   in	   brain	   imaging,	   detective	  haemostasis	  and	  multiple	  comorbidities	  with	  a	  limited	  life	  expectancy	  (3).	  	  	  Alteplase	   is	   a	   tissue	   plasminogen	   activator	   that	   converts	   plasminogen	   to	   plasmin,	   which	  degrades	   fibrin	   clots	   (7).	   Alteplase	   is	   given	   0.9	  mg/kg,	   a	  maximum	   of	   90	  mg,	   first	   10%	   by	  bolus	   and	   the	   rest	   by	   intravenous	   infusion	   during	   an	   hour	   (6).	  Heparin	   inactivates	   clotting	  factors	   such	   as	   thrombin,	   factor	   Xa	   and	   other	   proteases	   (7).	   Heparin-­‐infusion	   is	   used	   to	  prevent	  rethrombosis.	  Heparin	  is	  monitored	  using	  the	  activated	  partial	  thromboplastin	  time	  (APTT).	   In	   the	   last	   years,	   patients	  with	   BAO	   have	   been	   treated	  with	   low-­‐molecular-­‐weight	  heparin	   (LMWH)	   by	   bolus	   and	   subsequent	   subcutaneous	   enoxaparin	   0.75	   -­‐	   1	  mg/kg	   twice	  daily.	  (6)	  	  Some	   of	   the	   recognized	   outcome	   predictors	   include	   age,	   severity	   of	   stroke	   symptoms	  evaluated	  by	  National	  Institutes	  of	  Health	  Stroke	  Scale	  (NIHSS),	  time	  to	  treatment,	  occlusion	  length,	   thrombus	   volume,	   clot	   location,	   and	   possible	   collaterals	   (1).	   	   The	   absence	   of	  hyperlipidaemia	   and	   presence	   of	   prodromal	   minor	   stroke	   were	   associated	   with	   a	   poor	  outcome	  in	  a	  previous	  study	  (8).	  	  	  If	  a	  patient	  develops	  symptomatic	  intracranial	  haemorrhage	  (sICH),	  mortality	  increases	  and	  survivors	   have	   a	  worse	   prognosis	   (1).	   The	   known	   predictors	   of	   sICH	   after	   thrombolysis	   in	  BAO	  are	   age,	   baseline	  NIHSS,	   and	   admission	  blood	   glucose.	   In	   ischemic	   anterior	   circulation	  stroke	   patients,	   age	   >	   75	   years,	   NIHSS	   >	   10	   on	   admission	   and	   glucose	   >	   8	   mmol/l	   on	  admission	   predict	   the	   development	   of	   sICH.	   Also,	   early	   infarct	   signs	   and	   a	   dense	   cerebral	  artery	  sign	  in	  a	  CT	  head	  scan	  do	  increase	  the	  risk.	  (9)	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Here,	   we	   tested	   whether	   routine	   heparin	   infusion	   with	   IVT	   is	   associated	   with	   intracranial	  haemorrhage.	  The	   intention	  was	   to	   test	  demographic-­‐,	   physiological-­‐	   and	   treatment-­‐related	  factors	  affecting	  the	  development	  of	  symptomatic	  intracranial	  haemorrhage.	  The	  results	  have	  also	  been	  published	  as	  an	  original	  article,	  which	  is	  in	  the	  end	  of	  this	  thesis.	  (10).	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2	  	  	  	  	  Material	  
 The	   data	   were	   from	   a	   consecutive	   cohort	   of	   BAO	   patients	   treated	   at	   Helsinki	   University	  Central	   Hospital	   during	   the	   period	   between	   1995-­‐2013.	   The	   number	   of	   patients	   was	   176.	  Patients	   were	   treated	   with	   IV	   0.9	   mg/kg	   alteplase	   and	   immediately	   after	   or	   before	  thrombolysis	  with	   full-­‐dose	   anticoagulation	  with	   either	   intravenous	   unfractionated	   heparin	  (UFH)	  or	  LMWH.	  Heparin	  was	  continued	  until	  the	  patient	  was	  mobilized.	  The	  APTT	  target	  was	  between	   75	   and	   100	   seconds	   and	   it	   was	   monitored	   every	   4	   to	   6	   hours.	   If	   APTT	   values	  exceeded	  180	  seconds	  they	  were	  recoded	  to	  181	  seconds.	  	  We	   gathered	   the	   data	   from	   the	   electronic	   and	   paper	   patient	   charts	   manually	   and	   double-­‐checked	  a	  random	  sample.	  The	  data	  we	  gathered	  consisted	  of	   the	  age	  of	  patients;	  NIHSS	  on	  admission,	  right	  after	   the	   treatment	  and	  24	  hours	  after	   the	   treatment;	  whether	   the	  patients	  developed	  a	   symptomatic	   intracranial	  haemorrhage	   (sICH)	  or	  not	   and	   if	   they	  did,	   the	  delay	  between	   the	   treatment	   and	   sICH;	   haemoglobin	   on	   admission;	   the	   leukocyte	   count	   on	  admission;	  the	  thrombocyte	  count	  on	  admission	  and	  24	  hours	  after	  the	  treatment;	  proteinuria	  on	  admission;	  the	  creatinine	  level	  on	  admission;	  the	  APTT	  level	  on	  admission	  and	  the	  first	  ten	  APTT	   values	   registered;	   delays	   from	   heparin	   administration	   to	   each	   APTT	   value;	   maximal	  APTT	   values	   after	   heparin	   administration	   in	   every	   12	   hours	   up	   to	   120	   hours;	   systolic	   and	  diastolic	  blood	  pressure	  levels	  on	  admission	  and	  at	  2/4/8/12/24/48	  hours;	  blood	  glucose	  on	  admission	   and	   the	   highest	   blood	   glucose	   levels	   at	   days	   one	   to	   seven	   after	   intervention.	  Comparisons	   were	   made	   between	   the	   patients	   who	   developed	   sICH	   as	   a	   complication	   of	  intervention	  and	  those	  who	  did	  not.	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3	  	  	  	  	  Methods	  
 Statistical	   analysis	  was	   carried	  out	  using	   SPSS	   statistical	   software	  21.0.	  Distributions	  of	   the	  continuous	  variables	  were	  tested	  for	  normality.	  Univariate	  analyses	  were	  performed	  with	  the	  
t-­‐test	   or	   Mann–Whitney	   U	   test,	   as	   appropriate.	   We	   conducted	   a	   t-­‐test	   for	   blood	   pressure	  differences	   between	   sICH	   and	   non-­‐sICH	   groups.	   Non-­‐normal	   data	   were	   tested	   by	  nonparametric	   tests	   between	   sICH	   and	   non-­‐sICH	   groups.	   P-­‐values	   lower	   than	   0.05	   were	  considered	  significant.	  	  The	   extent	   of	   baseline	   ischemia	   was	   evaluated	  with	   the	   posterior	   circulation	   Acute	   Stroke	  Prognosis	   Early	   CT	   score	   (pc-­‐ASPECTS)	   for	   CT	   (69%	   of	   patients)	   and	   magnetic	   resonance	  imaging	   (MRI)	   (31%	   of	   patients).	   Post-­‐treatment	   CT	   or	  MRI	   was	   obtained	   about	   24	   hours	  after	   thrombolysis	   and	   additional	   CT	   if	   needed.	   sICH	   was	   judged	   according	   to	   European	  Cooperative	   Acute	   Stroke	   Study	   II	   (ECASS-­‐II)	   (11)	   .	   Recanalization	   was	   rated	   as	   partial	   to	  complete	   and	   nil	   to	  minimal	   in	   post-­‐treatment	   angiography.	  We	   used	   the	  modified	   Rankin	  Scale	  (mRS)	  at	  three	  months	  to	  rate	  the	  outcome.	  A	  favourable	  outcome	  was	  rated	  as	  0	  to	  2	  and	  unfavourable	  as	  3	  to	  6.	  MRS	  is	  explained	  in	  more	  detail	  in	  Table	  1.	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4	  	  	  	  	  Results	  
 Out	  of	  176	  BAO	  patients	  who	  were	  treated	  with	  alteplase	  and	  full-­‐dose	  heparin,	  24	  (13.6%)	  developed	   sICH.	  One	  patient	  died	  before	  CT	   scan	   control.	   90%	  of	   sICHs	  occurred	  within	  48	  hours	   from	   the	   treatment.	   Blood	   pressures	   at	   bleeding	   are	   estimates	   of	   the	   real	   pressures	  since	   the	   values	   taken	  were	   the	   closest	   ones	   to	   the	   detection	   of	   sICH	   on	   head	   scan.	   Blood	  pressure	  values	  were	  normally	  distributed.	  	  In	  Table	  2	  we	  present	  baseline	  characters	  of	  sICH	  and	  non-­‐sICH	  patients.	  Out	  of	  sICH-­‐patients	  there	  were	  8	  (33.3%)	  females	  and	  16	  (66.7%)	  males.	  The	  proportions	  didn’t	  differ	  compared	  to	  non-­‐SICH	  patients.	  Among	  the	  whole	  cohort,	  patients’	  mean	  age	  was	  65	  years	  and	  standard	  deviation	  14	  years.	  Diabetes	  mellitus	   type	   II	  was	  present	   in	  13.1%,	  hypertension	   in	  50.9%,	  previous	   stroke	   in	   23.4%,	   dyslipidaemia	   in	   37.1%	   and	   congestive	   heart	   failure	   in	   5.7%	   of	  cases.	   These	   demographics	   did	   not	   differ	   between	   sICH	   and	   non-­‐sICH	   patients.	  Medication	  including	   statins,	   antihypertensives,	   antiplatelets,	   insulin,	   oral	   diabetes	   medication	   and	  anticoagulation	  prophylaxis	  medication	  didn’t	  differ	  between	  sICH	  and	  non-­‐sICH	  patients.	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Table	  2.	  Baseline	  characters	  for	  patients	  with	  and	  without	  sICH.	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Parameter,	  median	  (IQR,	  range)	   sICH	  -­‐(n=151)	  	   sICH	  +(n=24)	  	   p-­‐value	  	  
Age,	  years	  	   64	  (18,	  27-­‐92)	  	   69	  (18,	  28-­‐94)	  	   0.354	  	  
Male	  	   101	  (66.9)	  	   16	  (66.7)	  	   1.000	  	  
Baseline	  NIHSS	   20	  (19,	  1-­‐42)	  	   25	  (20,	  3-­‐39)	   0.138	  	  
pc-­‐ASPECTS<8	   41	  (27.2)	  	   12	  (50)	  	   0.031	  	  
VB-­‐leucoaraiosis	  	   18	  (15.9)	  	   2	  (10.5)	  	   0.774	  	  
Baseline	  glucose,	  mmol/l	  	   7.1	  (3,	  4.2-­‐17.7)	  	   	  7.8	  (4.4,	  5.2-­‐18.5)‡	  	   0.324	  	  
Peak	  glucose<48	  h	  	   	  6.7	  (2.3,	  4.1-­‐16.7)†	  	   	  7.7	  (2.7,	  5.2-­‐15)§	  	   0.062	  	  
Baseline	  systolic	  BP,	  mmHg	  	   152	  (23)	  	   145	  (22)	  	   0.203||	  	  
Baseline	  diastolic	  BP	  	   83	  (17)	  	   76	  (18)	  	   	  0.070||	  	  
Systolic	  BP	  (2	  h)	  	   147	  (26)	  	   160	  (22)	  	   	  
0.034‡	  	  
Diastolic	  BP	  (2	  h)	  	   76	  (17)	  	   83	  (24)	  	   0.093‡	  
Baseline	  platelet	  count,	  E9/l	  	   218	  (81,	  82-­‐387)	  	   183	  (63,	  107-­‐312)	  	   	  
0.011‡	  	  
Baseline	  haemoglobin,	  g/l	  	   142	  (21,	  89-­‐186)	  	   138	  (28,	  96-­‐167)	  	   	  0.474#	  	  
Baseline	  leucocytes,	  E9/l	  	   9.1	  (3.7,	  2.7-­‐22.8)	  	   8.2	  (3.7,	  5.7-­‐17.3)	  	   	  0.404#	  	  
Baseline	  creatinine,	  μmol/l	  	   78	  (25,	  38-­‐272)**	  	   80	  (40,	  50-­‐180)	  	   0.159	  	  
Diabetes	  	   18	  (11.9)	  	   5	  (20.8)	  	   0.324	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*>85%	   data	   available;	   †76%	   availability;	   ‡>91%	   availability;	   §>66%	   availability;	   ||>98%	  availability;	  #94%	  availability;	  **96%	  availability.	  Mean	  (SD)	  for	  BP	  values.	  NIHSS=	  National	  institutes	  of	  health	  stroke	  scale;	  OTT=Onset	  to	  treatment	  time;	  VB=vertebro-­‐basilar.	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Prior	  antiplatelet	  	   40	  (26.5)	  	   9	  (37.5)	  	   0.327	  	  
Prior	  warfarin	  	   13	  (10.1)	  	   1	  (4.8)	  	   	  0.693*	  	  
OTT,	  min	  	   447	   (747,	   48-­‐10910)	  	   604	  (1151,	  85-­‐3015)	  	   0.256	  	  
Recanalization	  	   80	  (66.7)	  	   5	  (38.5)	  	   	  0.066†	  	  
Hypertension	  	   76	  (50.3)	  	   13	  (54.2)	  	   0.827	  	  Dyslipidaemia	  	   56	  (37.1)	  	   9	  (37.5)	  	   1.000	  	  
Atrial	  fibrillation	  	   33	  (21.9)	  	   6	  (25)	  	   0.792	  	  
Congestive	  heart	  failure	  	   10	  (6.6)	  	   0	  	   0.361	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Pc-­‐ASPECTS	  less	  than	  8	  points	  was	  considered	  as	  extensive	  ischemic	  changes	  on	  the	  basis	  of	  the	  original	  report	  (13).	  Patients	  with	  sICH	  more	  commonly	  had	  pc-­‐ASPECTS	  <8	  compared	  to	  non-­‐sICH	  patients	  (50%	  vs.	  27%,	  p	  =	  0.031).	  123	  (70.3%)	  patients	  had	  mRS	  3	  to	  6	  outcome	  three	  months	  after	  thrombolysis	  and	  these	  included	  all	  sICH	  cases.	  The	  mean	  delay	  from	  the	  treatment	   to	   sICH	  was	   21	   hours	   (SD	   18	   h,	   2.3-­‐73	   h).	   Three	  months	   after	   thrombolysis	   69	  (39.4%)	   patients	   had	   died	   and	   out	   of	   them	   22	  were	   sICH	   patients.	   Only	   two	   sICH	   patients	  survived	  (8,3%).	  	  Mean	  systolic	  blood	  pressure	   two	  hours	  after	   thrombolysis	  associated	  with	  development	  of	  sICH.	  The	  higher	  the	  pressure	  the	  greater	  the	  risk	  of	  sICH,	  mean	  160	  mmHg	  vs.	  non-­‐sICH	  147	  mmHg	  (p	  =	  0.034).	  Systolic	  blood	  pressure	  two	  hours	  after	  tPA	  administration	  was	  higher	  in	  patients	  with	   sICH	   than	  without	   sICH.	   	   This	   is	   shown	   in	   Figure	   1.	   The	   blue	   line	   represents	  patients	   without	   sICH	   and	   the	   red	   line	   patients	   with	   sICH.	   Diastolic	   blood	   pressure	   values	  didn’t	  differ.	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 Figure	  1.	  Median	  systolic	  blood	  pressures	  within	  the	  two	  groups.	  Blood	   glucose	   right	   after	   tPA	   administration	   and	  maximal	   values	   on	   the	   days	   1	   to	   7	   were	  equal	  between	  the	  groups.	  Median	  blood	  glucose	  is	  shown	  in	  Figure	  2.	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  Figure	  2.	  Median	  blood	  glucose	  between	  the	  two	  groups.	  	  Platelet	   count	   at	   baseline	   and	   24	   hours	   after	   tPA	   and	   heparin	   administration	  was	   lower	   in	  patients	  with	  sICH	  than	  with	  non-­‐sICH;	  183	  vs.	  218	  E9/l	  at	  baseline	  (p	  =	  0.011)	  and	  169	  vs.	  204	  E9/l	   at	   24	   h	   (p	   =	   0.035).	  Mean	   platelet	   count	   at	   baseline	   and	   at	   24	   hours	   is	   shown	   in	  Figure	  3.	  The	  blue	  lines	  represent	  patients	  without	  sICH	  and	  the	  red	  lines	  patients	  with	  sICH.	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  Figure	  3.	  Platelet	  count	  between	  the	  two	  groups.	  	  Figure	   4	   shows	   median	   APTT	   values	   measured	   before	   heparin	   infusion	   and	   after	   that	   in	  twelve-­‐hour	  periods	  up	  to	  120	  hours.	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  Figure	  4.	  Median	  APTT	  values	  at	  different	  times	  between	  the	  two	  groups.	  	  In	  Figure	  5	  there	  are	  median	  APTT	  values	  before	  heparin	   infusion	  and	  after	  that	  the	  first	  to	  tenth	  measured	  APTT	  values.	  It	  is	  seen	  that	  APTT	  values	  didn’t	  differ	  with	  sICH	  and	  non-­‐sICH	  patients	  so	  they	  didn’t	  correlate	  with	  developing	  sICH.	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 Figure	  5.	  	  Median	  APTT	  values	  in	  administration	  and	  the	  first	  to	  tenth	  measured	  APTT	  after	  the	  treatment.	  	  In	  Figure	  6	  there	  are	  the	  APTT	  values	  obtained	  closest	  to	  sICH	  detection.	  Red	  dots	  represent	  those	  five	  patients	   in	  whom	  the	  delay	  from	  APTT	  measurement	  to	  sICH	  detection	  was	  more	  than	   three	  hours.	  The	  black	  dots	   represent	  patients	   in	  whom	   the	  delay	  was	  <	  2	  hours.	  The	  blue	  x-­‐axis	  represents	  the	  peak	  and	  the	  range	  of	  APTT	  values	  per	  12-­‐hour	  intervals.	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 Figure	  6.	  The	  APTT	  values	  of	  sICH	  patients.	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5	  	  	  	  	  Discussion	  
 The	   main	   intention	   of	   this	   research	   was	   to	   determine	   whether	   the	   heparin	   treatment	  associates	   with	   the	   development	   of	   sICH.	   Heparin	   effect	   is	   measured	   by	   APTT	   values.	   We	  found	  only	  three	  factors	  that	  differed	  between	  patients	  with	  sICH	  and	  without	  sICH,	  and	  these	  were	   pc-­‐ASPECTS	   <8	   prior	   to	   treatment,	   the	   platelet	   count	   at	   baseline	   and	   24	   hours	   after	  treatment	   and	   systolic	   blood	   pressure	   two	   hours	   after	   treatment.	   A	   low	   to	   normal	  perithrombolytic	   platelet	   count	   was	   associated	   with	   sICH.	   The	   higher	   the	   systolic	   blood	  pressure	  at	  two	  hours,	  the	  higher	  the	  risk	  of	  sICH	  development.	  The	  mean	  blood	  pressure	  of	  sICH	   patients	  was	   160	  mmHg	   and	   that	   of	   non-­‐sICH	   patients	   147	  mmHg	   at	   2	   h.	   Both	   these	  were	  still	  below	  the	  acceptable	  185	  mmHg.	  Why	   is	   the	   two-­‐hour	  point	  significant	  while	   the	  other	  times	  are	  not?	  The	  blood	  content	  of	  actilyse	  (recombinant	  tissue	  plasminogen	  activator)	  is	   highest	   close	   to	   the	   infusion	   and	   2	   h	   was	   the	   first	   registered	   time	   of	   blood	   pressure	  measurements.	  	  Earlier	   studies	   have	   shown	   association	   of	   blood	   pressure	  with	   sICH	   after	   IVT	   in	   BAO.	   In	   a	  large	  study	  with	  11	  080	  patients	  high	  systolic	  blood	  pressure	  2	  to	  24	  hours	  after	  thrombolysis	  was	  associated	  with	  poor	  outcome	  and	  sICH.	  The	  optimal	  systolic	  blood	  pressure	  values	  were	  141	   to	   150	  mmHg	   and	   predicted	   the	   best	   outcome.	   If	   antihypertensives	  were	   given	   to	   the	  newly	   recognized	  moderate	  hypertensive	  patients	   that	  predicted	   favourable	  outcome.	   	   (14)	  	  In	  another	  smaller	  study	  there	  wasn’t	  association	  with	  high	  blood	  pressure	  and	  sICH	  but	  there	  was	  poorer	  outcome	  with	  higher	  blood	  pressures	  (15).	  	  Platelet	   count	   in	   association	   to	   sICH	   has	   not	   been	   studied	   extensively	   before	   in	   our	   best	  knowledge.	  Nevertheless	  there	  have	  been	  studies	  that	  show	  that	  antiplatelet	  agents	  associate	  with	   developing	   ICH	   after	   recombinant	   tPA.	   Also	   an	   association	   between	   sICH	   and	   atrial	  fibrillation,	   leucoaraiosis,	   congestive	   heart	   failure,	   higher	   age	   and	   higher	   glucose	   has	   been	  shown	  in	  a	  large	  meta-­‐analysis	  with	  65	  264	  acute	  ischemic	  stroke	  patients.	  	  (16)	  	  In	  our	  study	  there	  wasn’t	  any	  association	  between	  congestive	  heart	  failure	  and	  sICH	  but	  there	  were	  very	  few	  patients	  with	  this	  condition.	  We	  didn’t	  find	  any	  correlation	  with	  age	  and	  developing	  sICH	  in	   accordance	  with	   a	   prior	   study	   (17),	   but	   there	   is	   also	   previous	   study	  with	   larger	   sample	  showing	  age	  as	  a	  predictor	  of	  sICH	  (9).	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In	  the	  present	  study	  half	  of	  the	  patients	  with	  sICH	  had	  pc-­‐ASPECTS	  <8	  and	  all	  sICH	  patients	  had	   unfavourable	   outcome	   (mRS	   3-­‐6).	   In	   a	   larger	   study	   with	   619	   BAO-­‐patients	   extensive	  ischemic	   changes	   on	   baseline	  were	   a	   predictor	   for	   poor	   outcome	   and	   in	   a	  meta-­‐analysis	   of	  acute	   ischemic	  stroke	  patients	   treated	  with	  recombinant	   tPA	  they	  were	  a	  predictor	   for	   IVT-­‐associated	   sICH(8,16).	   The	   APTT	   values	   didn’t	   differ	   in	   patients	  with	   or	  without	   sICH	   and,	  indeed,	  over	  50%	  of	  sICH	  patients	  had	  targeted	  APTT	  values	  (75-­‐100).	  	  Early	   hyperglycaemia	   can	   increase	   the	   risk	   of	   early-­‐term	  death	   of	   spontaneous	   intracranial	  haemorrhage	  patients	  when	  hyperglycaemia	  is	  defined	  to	  be	  more	  than	  7.5	  mmol/l	  (18).	  The	  admission	  blood	  glucose	  over	  8	  mmol/l	  was	  a	  predictor	  for	  sICH	  in	  a	  larger	  patient	  cohort	  (9)	  but	  in	  our	  study	  there	  wasn’t	  correlation	  between	  sICH	  and	  high	  admission	  blood	  sugar.	  Most	  of	   our	  patients	   had	   their	   blood	   glucose	  under	  10	  mmol/l	   and	   that	   could	  partly	   explain	   our	  results.	   The	   gender	   didn’t	   have	   association	   with	   developing	   sICH	   in	   our	   study	   and	   this	   is	  similar	  to	  another	  study	  (19).	  	  Our	  study	  may	  be	  biased	  by	  some	  factors.	  The	  cohort	  is	  from	  a	  single	  centre	  and	  the	  sample	  size	  is	  quite	  small,	  yet	  BAO	  is	  a	  rare	  form	  of	  ischemic	  stroke	  and	  sICH	  is	  more	  rare	  a	  condition.	  IVT	   treatment	   is	   the	   routine	   BAO	   treatment	   used	   in	   Helsinki,	   Finland.	   Missing	   data	   was	  highest	   for	   blood	   glucose	   after	   the	   hyperacute	   period	   and	   proportion	   of	   missing	   data	   was	  higher	   for	  patients	  with	   sICH	   than	  without	   sICH	  at	   later	   time	  points	   (34%	  vs.	   24%	  <	  48	  h;	  Table	  2).	  This	  most	  probably	  correlates	  with	   the	  severe	  condition	  of	   the	  patients	   leading	   to	  omitting	  the	  glucose	  measurements.	  	  In	  further	  studies	  it	  would	  be	  interesting	  to	  analyse	  more	  intensively	  the	  long-­‐term	  quality	  of	  the	  lives	  of	  BAO	  patients.	  Another	  very	  important	  improvement	  would	  be	  to	  compare	  IVT	  and	  IAT	   treatments	   in	   randomized	   controlled	   trial,	   but	   that	   is	   not	   likely	   to	   happen.	   Present	  research	  should	  be	  continued	  with	  bigger	  sample	  size	  so	  the	  results	  would	  be	  more	  reliable	  and	  there	  could	  be	  strategies	   to	  minimize	   the	  risk	  of	  sICH.	  Our	  patient’s	  APTT	  values	  didn’t	  affect	  developing	  sICH	  but	  if	  they	  targeted	  lower	  would	  the	  results	  be	  different	  or	  would	  the	  use	  of	  LMWH	  give	  more	  even	  anticoagulation?	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6	  	  	  	  	  Conclusions	  
 We	   found	   three	   factors	   that	   associated	   with	   the	   development	   of	   sICH.	   Extensive	   baseline	  ischemic	  changes,	  i.e.	  pc-­‐ASPECTS	  under	  8,	  was	  the	  most	  significant	  factor	  which	  made	  sICH	  more	  likely.	  Clinically	  significant	  factors	  also	  included	  a	  low	  to	  normal	  platelet	  count	  and	  high	  systolic	   blood	   pressure	   at	   2	   hours	   after	   treatment.	   However,	   more	   studies	   are	   needed	   to	  confirm	  these	  findings.	  APTT	  values	  didn’t	  have	  association	  with	  sICH.	  The	  results	  are	  in	  line	  with	   previous	   studies	   showing	   association	   of	   blood	   pressure	   with	   sICH	   and	   maybe	   in	   the	  future,	   we	   should	  more	   actively	   treat	   the	   blood	   pressure	   of	   BAO	   patients,	   even	   below	   the	  present	  guidelines,	  to	  prevent	  symptomatic	  intracranial	  haemorrhage.	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Background and purpose: Our aim was to determine factors associated with
symptomatic intracranial haemorrhage (sICH) in basilar artery occlusion
patients treated with intravenous thrombolysis (IVT) and adjuvant anticoagu-
lant therapy.
Methods: A registry of 176 consecutive patients with angiography-proven bas-
ilar artery occlusion who received IVT with alteplase and heparin between
1995 to 2013 was assessed. Post-treatment sICH was evaluated with the Euro-
pean Cooperative Acute Stroke Study II criteria. Unfavourable outcome was
defined as a modified Rankin Scale score of 3–6 at 3 months.
Results: Twenty-four patients developed sICH (13.6%, sICH+), all of whom
had unfavourable outcome and only two (8.3%) sICH+ patients survived. On
admission, sICH+ patients more frequently had extensive ischaemic changes
defined as posterior circulation Acute Stroke Prognosis Early CT Score (PC-
ASPECTS) < 8 (50% vs. 27% in sICH!, P = 0.031) and lower platelet counts
(183 vs. 218 E9/l; P = 0.011). They also had higher systolic blood pressure
(SBP) (median 160 vs. 147 mmHg, P = 0.034) immediately after IVT. In mul-
tivariable regression analysis, lower platelet values [odds ratio (OR) 0.99, 95%
confidence interval (CI) 0.97–0.996; P = 0.006], PC-ASPECTS < 8 on admis-
sion (OR 3.6, 95% CI 1.3–10.3; P = 0.017) and higher SBP after treatment
(OR 1.03, 95% CI 1.01–1.05; P = 0.017) were independently associated with
sICH. Ninety per cent of the sICHs occurred within 48 h from IVT/anticoagu-
lation treatment. No diﬀerences in activated partial thrompoplastin times prior
to or after the treatment were observed between sICH+ and sICH! patients.
Conclusions: The risk of sICH was largely determined by extension of ischae-
mic changes on admission computed tomography. Clinically relevantly, also
higher post-thrombolytic SBP as described earlier and lower perithrombolytic
platelet counts do increase the risk, a finding requiring confirmation in other
patient series.
Introduction
In posterior circulation strokes and basilar artery occlu-
sion (BAO), the occurrence of post-thrombolytic intra-
cranial haemorrhage (ICH) has occasionally been
reported to be lower than in anterior circulation strokes
[1,2], although another registry reported a rate reason-
ably in line with anterior circulation strokes [3]. The
rates of symptomatic intracranial haemorrhage (sICH)
in BAO have varied from 6% [3] even up to 30% with
an endovascular multimodal approach [4], but the defi-
nitions of (s)ICH were not uniform. The issue of sICH,
however, is crucial in BAO since in addition to variable
recanalization therapies many centres apply anticoagu-
lation [5] despite lack of formal guidelines (Table 1).
Our long-standing in-house protocol also recommends
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starting full anticoagulation at the time of thrombolysis
whenever a BAO diagnosis has been established and
intracranial haemorrhage ruled out on admission head
scan [6–8]. Incentives to this empirically evolved
approach have been recurrent posterior circulation
strokes and re-occlusions, reported to occur at rates
from 10% up to 30% [9,10].
A recent meta-analysis on post-thrombolytic sICH
concluded that similar factors predict both ICH and
poor outcome [11]. In hemispheric stroke thromboly-
sis, the SEDAN score including admission blood
sugar >8 mmol/l, early infarct and dense artery signs
on computed tomography (CT), age >75 years and
National Institutes of Health Stroke Scale (NIHSS)
≥10 predicts development of sICH [12]. Age and
stroke severity are strong predictors across all sICH
risk scores [13,14]. A reliable way is still being sought
to predict sICH after BAO recanalization therapies.
Since the development of sICH showed a strong corre-
lation with poor outcome and death after BAO intrave-
nous thrombolysis (IVT) in our previous analysis [7],
this led us to analyse factors associated with post-throm-




The cohort consisted of 176 consecutive BAO patients
treated with intravenous 0.9 mg/kg recombinant tissue
plasminogen activator (rtPA) and concomitant unfrac-
tionated heparin (UFH) in Helsinki University
Central Hospital from 1995 to April 2013. All patients
were registered prospectively and additional data were
retrieved from patient charts. All cardiovascular con-
ditions refer to a diagnosis prior to BAO [6–8]. No
approval by the ethical committee was required as
data were collected as part of routine care.
Physiological and laboratory variables
Systolic and diastolic blood pressures (BPs) were mea-
sured prior to, during (between 15 min intervals up to
2 h) and after (30 min intervals up to 8 h and 60 min
up to 24 h). BP values on admission and at 2, 4, 8, 12,
24 and 48 h after tPA administration were registered.
Blood glucose on admission and maximal levels on days
1!7 were registered. Laboratory data included admis-
sion whole blood and platelet counts and creatinine
concentration. During anticoagulation with UFH, a
target activated partial thromboplastin time (APTT)
was set between 75 and 100 s. The dynamics of APTT
values from admission to the tenth consecutive value or
until discontinuation of heparin treatment or until sus-
picion/detection of sICH (when heparin was stopped)
were analysed. All APTT values exceeding 180 s were
recoded to 181 s. Delays between heparin administra-
tion and each consecutive APTT value were also regis-
tered along with maximal APTT values for each 12 h
interval up to 120 h.
Imaging
The extent of baseline ischaemia was evaluated with
the posterior circulation Acute Stroke Prognosis Early
Table 1 Multimodal recanalization therapies and treatment associated intracranial bleeding complications (sICH) in BAO patient series with
adjunctive anticoagulation (AC)
Therapy modality Number of patients AC sICH n (%)
IVT or IVT + EMR [35] 16 ASA, IV heparin, or glycoprotein IIb/IIIa
inhibitor
1/16 (0.06)a
IAT [36] 16 IV unfractionated heparin for 24 h 2/16 (12.5)
IAT [1] 106 IV ASA/no heparin 1/106 (0.9)b
IVT/bridging + IAT or IVT/IAT + EMR [4] 91 Peritreatment heparin 22/74 (29) or 5/17 (30)
IVT + EMR [37] 53 Heparin bolus every hour after Tx (duration
not given)
8/53 (15)c
EMR [38] 28 On demand periprocedural AC 3/28 (11)d
EMR [39] 16 Periprocedural heparin 6/16 (38)e
EMR " IAT [40] 81 Periprocedural heparin 14/81 (23)f
EMR " IAT [41] 24 On demand periprocedural IV aspirin, heparin
or tirofiban
2/24 (8)g
IVT/present study 176 IV heparin infusion 24/176 (14)
Note that the definitions of sICH vary between studies.IVT, intravenous thrombolysis; IAT, intra-arterial thrombolysis; EMR, endovascular
mechanical recanalization; ASA, acetylsalicylic acid; Tx, treatment.
aICH, lethal; bPROACT II criteria; cbleeding complications including subarachnoid haemorrhage, parenchymal haemorrhage and intraventric-
ular haemorrhage; dpost-procedure ICH (one lethal); ehaemorrhagic infarction; fdissections and subarachnoid haemorrhage; gincluding four
dissections.
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CT Score (PC-ASPECTS) for either CT (n = 121/176,
69%) or magnetic resonance imaging (MRI) (31% of
patients). PC-ASPECTS <8 represented extensive is-
chaemic changes [15]. Post-treatment CT or MRI was
obtained in all patients approximately 24 h after
thrombolysis and additional CT was obtained when-
ever clinical deterioration occurred or ICH was sus-
pected. sICH was judged according to European
Cooperative Acute Stroke Study II (ECASS II) crite-
ria [16]. Thrombolysis in myocardial infarction (TIMI)
was scored from post-treatment CT angiography
(n = 53; 41%) and time-of-flight MR angiography
(n = 78). Recanalization was dichotomized as partial
to complete (TIMI 2–3) and nil to minimal (TIMI 0–
1) in post-treatment angiography [17] available for
131 of 176 patients (74%) with the preference of using
the same modality as for pre-treatment angiogram.
All radiological data were evaluated in a blinded
fashion.
Clinical outcome
Unfavourable outcome was rated as modified Rankin
Scale (mRS) 3–6, favourable outcome as mRS 0–2.
mRS was assessed by video-trained, certified stroke
neurologists either by appointment or by telephone
interview of patients or caregivers.
Statistical analysis
Distributions of the continuous variables were tested for
normality. Univariate analyses were performed with the
t test or the Mann–Whitney U test, as appropriate.
Dichotomous variables were compared with the Fisher
exact test. Data availability <99% is acknowledged in
the table footnotes. Finally, a model of backward binary
logistic regression was constructed studying factors
associated with sICH. Parameters with P < 0.1 in uni-
variate analysis and data availability >90% were
included in order to avoid selection bias and overfitting.
Two-sided values of P < 0.05 were considered signifi-
cant. SPSS 21.0 (IBM, Armonk, NY, USA) was used.
Results
Out of 176 BAO patients treated with IVT and full-
dose heparin, 24 (13.6%) developed sICH. One
patient died prior to control CT scan. All patients
with sICH scored mRS 3–6 at 3 months compared
with 65.6% of patients without sICH (P < 0.0001).
Twenty-two of 24 patients (91.7%) with sICH died.
The mean delay from IVT start to sICH was 21 h
(SD 18, 2.3–73 h). Demographics of patients with and
without sICH, the admission parameters and their
follow-up values are given in Table 2.
Table 2 Baseline characteristics for patients
with and without sICH. Post-thrombolytic
blood pressure (BP) and peak blood glu-
cose inside 48 h are also shown
Parameter, median (IQR) or n (%) sICH! (n = 151) sICH+ (n = 24) P
Age, years 64 (18, 27–92) 69 (18, 28–94) 0.354
Male 101 (66.9) 16 (66.7) 1.000
Diabetes 18 (11.9) 5 (20.8) 0.324
Hypertension 76 (50.3) 13 (54.2) 0.827
Dyslipidaemia 56 (37.1) 9 (37.5) 1.000
Atrial fibrillation 33 (21.9) 6 (25) 0.792
Congestive heart failure 10 (6.6) 0 0.361
Prior antiplatelet 40 (26.5) 9 (37.5) 0.327
Prior warfarin 13 (10.1) 1 (4.8) 0.693a
Baseline NIHSS 20 (19, 1–42) 25 (20, 3–39) 0.138
OTT, min 447 (747, 48–10 910) 604 (1151, 85–3015) 0.256
PC-ASPECTS < 8 41 (27.2) 12 (50) 0.031
VB-leucoaraiosis 18 (15.9) 2 (10.5) 0.774
Recanalization 80 (66.7) 5 (38.5) 0.066b
Baseline glucose, mmol/l 7.1 (3, 4.2–17.7) 7.8 (4.4, 5.2–18.5)c 0.324
Peak glucose < 48 h 6.7 (2.3, 4.1–16.7)b 7.7 (2.7, 5.2–15)d 0.062
Baseline systolic BP, mmHg 152 (23) 145 (22) 0.203e
Baseline diastolic BP 83 (17) 76 (18) 0.070e
Systolic BP (2 h) 147 (26) 160 (22) 0.034c
Diastolic BP (2 h) 76 (17) 83 (24) 0.093c
Baseline platelet count, E9/l 218 (81, 82–387) 183 (63, 107–312) 0.011c
Baseline haemoglobin, g/l 142 (21, 89–186) 138 (28, 96–167) 0.474f
Baseline leucocytes, E9/l 9.1 (3.7, 2.7–22.8) 8.2 (3.7, 5.7–17.3) 0.404f
Baseline creatinine, lmol/l 78 (25, 38–272)g 80 (40, 50–180) 0.159
Mean (SD) for BP values. OTT, onset to treatment time; VB, vertebro-basilar.
a>85% data available; b76% availability; c>91% availability; d>66% availability; e>98% avail-
ability; f94% availability; g96% availability. Bold indicates significant value (P < 0.05).
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Systolic BP was higher in patients with than with-
out sICH 2 h after rtPA infusion, without significant
changes thereafter (Fig. 1a). Blood glucose levels did
not diﬀer between patients with and without sICH
(Fig. 1b).
The time until first follow-up APTT measurement
was similar for patients with and without sICH with a
median of 4 h (IQR 2.5; range 0.5–21.5) and 4.5 h
(2.5; 2–16.5), respectively. Thereafter, the intervals
were 4–6 h in both groups and followed the institu-
tional guideline. There were no diﬀerences in the max-
imum or consequent APTT values on repeated
measurements between patients with and without
sICH (Fig. 2a). Figure 2b shows the most relevant
APTT values, i.e. those that were obtained very close
to the detection of sICH. The admission platelet count
was significantly lower in patients with sICH and
remained lower at 24 h after IVT (Fig. 3).
In multivariable regression analysis extensive base-
line ischaemic changes, lower platelet count on admis-
sion and higher systolic BP at 2 h were associated
with sICH (Table 3).
Discussion
The detailed data from the present cohort allow us to
estimate what aﬀects the occurrence of sICH after
IVT with adjuvant anticoagulation in BAO patients.
Half of the patients with PC-ASPECTS score <8 cor-
responding to extensive ischaemic changes experienced
sICH. Randomized clinical trials have studied mostly
anterior circulation strokes, and early infarct signs
exceeding one-third of the middle cerebral artery sup-
ply area are considered a contraindication for IVT
[18]. In BAO no such cut-oﬀ exists, naturally also due
to the lethal course of the disease if left untreated.
Besides extensive baseline ischaemia, increased BP
immediately after IVT and low-normal perithromboly-
sis platelet count are associated with sICH risk as
well. The latter modifiable factors could be amenable
to future therapeutic strategies that aim at minimizing
the sICH risk besides the evident need for recanaliza-
tion therapies.
The frequency of sICH per the ECASS II criteria in
our protocol with full-dose heparin was 14% which is
comparable to or smaller than reported for intra-arte-
rial thrombolysis, mechanical devices and the bridging
approach (Table 1) but higher than the 6% reported
from the BASICS registry [19].
Systolic BP was higher in patients with sICH
(160 mmHg) than without sICH (147 mmHg) 2 h
after starting rtPA (Fig. 1a), yet it was far below the
185 mmHg considered acceptable after IVT [18]. The
inherent eﬀect of high BP variability on sICH cannot
be captured by multivariate analysis due to the small
number of sICHs in our patient cohort, similar to a
German IVT-treated cohort [20], but the eﬀect is evi-
dent in larger cohorts [21].
Extensive ischaemic changes on baseline scan have
been found by us [7] and others [22] to predispose to
sICH after BAO treatment and were also a strong
predictor for IVT-associated sICH in a meta-analysis
sICH+ 22 21 16 8 5 2 2 2
sICH– 150 131 117 110 86 65 51 41
sICH+ 22 22 13 16 17 17 11
sICH– 148 142 116 127 132 141 127
(a)
(b)
Figure 1 Systolic blood pressure (SBP) and blood glucose prior
to and after treatment. (a) Mean (SD) SBP in patients with
sICH (red) and without sICH (blue) diﬀered only at 2 h after
tPA administration (*P = 0.034). The number of patients with
documented with sICH for each time interval is shown. (b) Med-
ian (IQR) blood glucose did not diﬀer between patients with
sICH (red) and without sICH (blue) at baseline or after treat-
ment. d, day(s).
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on ischaemic stroke [11]. The predictive value of the
NIHSS score for the presence of artery occlusion was
suggested to be poorer in the posterior circulation
than in the anterior circulation [23], and the cut-oﬀ
value for baseline NIHSS for favourable outcome was
found to be lower in posterior circulation than in
anterior circulation strokes [24]. Last but not least, in
line with the BASICS registry showing no eﬀect of
age >75 years on the incidence of sICH age was not
found to be an independent risk factor either [25].
The possible eﬀect of lower thrombocyte count on
post-thrombolytic sICH has been investigated in only
a few studies [11]. Prior observation of an association
between low platelet count and any post-thrombolytic
ICH [26] agrees with our finding that it predisposes
also to a sICH. However, our data do not show any
antiplatelet or warfarin use to be associated with
sICH as suggested in a meta-analysis on stroke IVT
[11], although such medications could intuitively
potentiate the eﬀect of lower platelet count to pro-
mote sICH formation. Perhaps something could be
learned from the prior stroke literature on platelets
and spontaneous ICH expansion, yet results are con-
flicting [27]. Anyhow, a randomized study on platelet
transfusion is under way in ICH patients [28]. Wis-
dom should be adopted across stroke subtypes, since
in traumatic ICH the need for platelet transfusion is
suggested to be guided by antiplatelet assay results
[29].
Animal experiments have suggested that heparin
enhances the thrombolytic eﬀect of rtPA [30,31]. Hep-
arin induced thrombocytopenia is an adverse event in
patients receiving UFH and usually occurs after a
week [32]. In none of our patients was the perihaem-
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69 (50-108) 70 (57-86) 79 (64-103) 77 (63-95) 80 (62-93) 76 (60-94) 76 (60-94)
(a) (b)
Figure 2 Activated partial thrombin time (APTT) values and sICH. (a) There were no diﬀerences in peak APTT values between
patients with (red) and without (blue) sICH. The two drops in the peak APTT values are explained by the detection of almost 70% of
sICHs by 24 h and all sICHs by 73 h after tPA injection. (b) The most relevant APTT values obtained time-wise closest to sICH
detection. The red dots represent five patients in whom the delay between APTT measurement and sICH detection was >3 h; in all
other patients it was ≤2 h. For comparison, the peak (median, IQR) APTT values per 12-h intervals in patients without sICH are out-
lined in blue on the x axis.
Table 3 Logistic regression on parameters associated with sICH
development after treatment with IVT and full-dose heparin in BAO
patients
OR 95% CI P
Platelet count at baseline 0.99 0.97–0.996 0.006
PC-ASPECTS <8 at baseline 3.6 1.26–10.27 0.017


























Figure 3 Perithrombolytic platelet counts and sICH. The plate-
let counts were lower in patients with sICH (red) than without
sICH (blue) at baseline and 24 h after IVT and full-dose heparin
treatment. *P = 0.011 at baseline; *P = 0.035 at 24 h.
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case was heparin induced thrombocytopenia clinically
confirmed. Since no correlation was found between
APTT and sICH, a full-dose anticoagulant regimen
was continued in BAO thrombolysis. However, our
current protocol advises a target of 2.0!2.5-fold the
baseline APTT levels and heparin dosing is adjusted
by weight [33]. At present, UFH has been replaced by
low-molecular-weight heparin in most acute cardiac
indications including ST-elevation myocardial infarc-
tion [34].
The shortcomings of our study are that the cohort
is derived from a single centre and the partly retro-
spective nature of the data collection. Yet the treat-
ment protocol has remained stable for a long time
and access to original patient data was available. The
relatively low number of sICHs underpowers statisti-
cal analysis. Our data on IVT and anticoagulation
may naturally not be transferable to centres where
BAO patients receive only IVT. In the absence of a
non-anticoagulated reference group firm conclusions
on the role of anticoagulation in development of sICH
cannot be drawn.
In conclusion, these data encourage vigilance for a
burden of multiple, concomitant sICH risk factors in
BAO thrombolysis, especially in severely ill patients
with extensive baseline ischaemic changes in the verte-
bro-basilar area. Intensive follow-up and treatment of
BP even below guidelines may be warranted if the risk
of sICH is estimated as high due to multiple coexis-
ting factors, possibly including also a low platelet
count.
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